Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Vistagen Therap. Com (VTGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 26,657
  • Shares Outstanding, K 21,850
  • Annual Sales, $ 1,250 K
  • Annual Income, $ -10,260 K
  • 36-Month Beta -3.33
  • Price/Sales 21.15
  • Price/Cash Flow N/A
  • Price/Book N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.05 +15.24%
on 12/29/17
1.42 -14.79%
on 01/16/18
+0.10 (+9.01%)
since 12/19/17
3-Month
0.69 +75.36%
on 11/29/17
2.65 -54.34%
on 12/07/17
+0.08 (+7.08%)
since 10/19/17
52-Week
0.69 +75.36%
on 11/29/17
3.52 -65.63%
on 01/27/17
-2.19 (-64.41%)
since 01/19/17

Most Recent Stories

More News
VistaGen Therapeutics Receives FDA Fast Track Designation for AV-101 for the Treatment of Major Depressive Disorder

SOUTH SAN FRANCISCO, CA--(Marketwired - January 03, 2018) - VistaGen Therapeutics, Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression...

VTGN : 1.21 (-0.82%)
3 Drug/Biotech Stocks Up More Than 10% This Week

The drugs/biotech sector is down this week due to broader market pressure, except a few stocks.

SCMP : 17.95 (unch)
AGN : 181.33 (+0.94%)
VTGN : 1.21 (-0.82%)
RVNC : 33.95 (+0.59%)
Wired News - VistaGen Receives US Patent on Methods for Producing Blood Cells, Platelets, and Bone Marrow Stem Cells

Stock Monitor: Pluristem Therapeutics Post Earnings Reporting

VTGN : 1.21 (-0.82%)
PSTI : 1.51 (+0.67%)
3 Drug/Biotech Stocks Up More Than 10% This Week

The drugs/biotech sector is down this week due to broader market pressure, except a few stocks.

SCMP : 17.95 (unch)
AGN : 181.33 (+0.94%)
VTGN : 1.21 (-0.82%)
RVNC : 33.95 (+0.59%)
Multi-Billion Dollar Global Medical Device Industry Led by Cardiovascular Monitoring Devices

Global revenues for the medical device market are already a multi-billion dollar industry and the sector aims to continue its growth through leverage created through mergers and acquisitions, as well as...

LNB.CN : 0.530 (unch)
NCI : 19.96 (+1.42%)
LXGTF : 0.4000 (-7.36%)
MDGL : 124.59 (+11.57%)
BEAT : 33.55 (+1.67%)
VTGN : 1.21 (-0.82%)
IMMU : 15.99 (+0.95%)
VistaGen Soars on Patent Announcement, Pipeline Review, and Analysts Opinion

NEW YORK, NY / ACCESSWIRE / December 7, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive...

VTGN : 1.21 (-0.82%)
Today's Research Reports on Stocks to Watch: Madrigal Pharmaceuticals and VistaGen Therapeutics

NEW YORK, NY / ACCESSWIRE / December 7, 2017 / Shares of Madrigal Pharmaceuticals and VistaGen were both on fire in Wednesday trading. Madrigal Pharmaceuticals announced positive data from mid-stage results...

MDGL : 124.59 (+11.57%)
VTGN : 1.21 (-0.82%)
VistaGen Therapeutics Granted U.S. Patent regarding Methods of Production for AV-101

SOUTH SAN FRANCISCO, CA--(Marketwired - December 06, 2017) - VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression...

VTGN : 1.21 (-0.82%)
VistaGen Therapeutics Reports Second Fiscal Quarter 2018 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, CA--(Marketwired - November 09, 2017) - VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression...

VTGN : 1.21 (-0.82%)
VistaGen Therapeutics Reports Second Fiscal Quarter 2018 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, CA--(Marketwired - November 09, 2017) - VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression...

VTGN : 1.21 (-0.82%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More

Business Summary

VistaGen Therapeutics, Inc. is a biotechnology company. It is engaged in developing and commercializing product candidates for diseases and disorders involving the central nervous system. The company's lead product candidate consists of AV-101, is an orally available prodrug candidate in Phase II development,...

See More

Key Turning Points

2nd Resistance Point 1.23
1st Resistance Point 1.22
Last Price 1.21
1st Support Level 1.20
2nd Support Level 1.19

See More

52-Week High 3.52
Fibonacci 61.8% 2.44
Fibonacci 50% 2.11
Fibonacci 38.2% 1.77
Last Price 1.21
52-Week Low 0.69

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.